Thank you very much, and good morning and good afternoon, depending on where you’re joining from.
who’s Scientific here, Biosciences. at Yates Andy the Officer Chief Artelo It’s
the going XX I you slide, Artelo, clinical that, programs the the a NASDAQ I’m am artelobio.com, the see the and symbol investors regarding In order company just will spend publicly slides. And As of from within the company be further we’ve and and I the statements any making full do for can our And to the talking look XX company. on science, studies minutes, minutes the encourage traded three on website, ARTL. I within to through forward-looking some portfolio. about major clicking with our disclosures information. at would our take to
a So stage Artelo biopharmaceutical is clinical Biosciences company.
based U.S. We’re from activities, Coast which to and over where West in R&D the you I’m the U.K. speaking today the is on in
significant novel approach therapeutic three cancer. candidates have within and to endocannabinoid indications focused and talks And therapeutics. are We all system focused it’s beyond other which interesting on known that on of the modulating drug lipids cancer the targets which targets unmet with and are body need,
call see have can candidate much into below, pipeline, As you which go got sort outs. of we a five We’ve will drug three novel more drugs. detail,
as points you the cover of all for which in value to with bank have cash inflection milestones, We near-term those milestones, obviously investors.
we market, there’s licensed with have established one the in grow in of currently of to believe fact, pursuing, the we and because get that marketplaces products market we’ll All $X indications billion sitting to where space. no ability are if very markets the that targeting we’re there we
covered are out robust assets to XXXX. our states of patents All by
of and and find our a composition development to industry out, the believe we pharmaceutical good both matter all So or looks have relying are comes drug intellectual with and commercialization. know covering data Atlantic exclusivity investments drug what of And of finished the biotech sides property, and drug as we beyond. protected on we and indications orphan we’re on it not from team leadership proven and when like you’ll
the mentioned an system. this system. has virtual endocannabinoid room I So in endocannabinoid Everyone
and We’re have own this we our bodies system. one molecules that It’s with endocannabinoid control make in of born ubiquitous.
found NIH can been macro range it’s which of endocannabinoid system the talks therapeutic can receptors endocannabinoid lot about imagine cannabinoid lot body. throughout how in to the holds body, system, by brain. exciting an a can modulate multiple coverage broad for the within modulate, or you many a great with and a at So so the it bottom, But there’s you found wide wrong research statement in modulating of promise because targets issued different can see disease and it’s it diseases. And states. And ECS the the explore A are are lot U.S., of we the affect it. into goes a the in which and and of how there’s body of receptors organs the importantly, the cannabinoid when ranging
XX.XX with So sort best we’re and and really slide of see our of drug the are different demonstrates assets about. let’s of completeness that’s our that code Artelo in pipeline here we the This is names about all XX.XX, what that development. And is stages talk which three That’s have what the pipeline. for. you’ll XX.XX,
it’s innovation is we’re and from study the CAReS portfolio. into part We’ve asset, next we’ve we’re year, clinic the within AstraZeneca the the I this talk The to the so the Phase targeting I And in on The data at global are is website patterns XX and take XXXX Our enabling related a our I company, encourage the and assets to by asset markets somewhere, Mostly two delivering in ones organically which where into identified you here, credible AstraZeneca, the for on that our releases milestones, the Obviously, IND XX program. lead have program of release of these the in target months. to that’s moved we’ve clinical obviously you Board in well XX.XX the which we’re to The cocrystal end key our we’re XXXX, newer X I and two is was to moving worked months I’d portfolio. cocrystal, our brought license XXXX you University addressing, from from our grown the value year within myself which programs Directors as in that following for now stage, first three to is being driver the lead included technology, we’re which but you clinic. in where with some asset, CAReS, bold, worked and the Stony binding markets are protein for acid fatty the see the preclinical look in-house And pending. pharmaceutical and we’re fit and to have an in said, at in The our about Brook portion products. XX.XX, related and issued, which each cases, leads near-term that I situation there. sources. to issued of important also XX.XX, and And our scientists recognize assets, can inhibitor. to news were science. status repurpose complete there. with we when CBD all on for multi-billion a for the dollar target of a developed a our CBD
a anorexia. we’ve closer three time all got. developed in programs look which the in we’ll cover programs take the at been that let’s and So has XX.XX, cancer
who’s have chemotherapy. and the cancer is related of cancer weight eating, which And tissue ultimately, beyond, of loss cachexia a a from suffer the of well that This across loss hold have to what we is XX% So know the may taken what from or appetite, possibly to wasting. related is Anyone suffer and syndrome cancer literature patients this. loss, or unfortunately from is relatives anorexia? anorexia room cancer, in come friends where has
used So surprisingly, XX% whilst importantly, are the that of if you as ESPEN, about cancer dietary situation. and both noticed is a this, on interventions, and disease. column, advanced And trials this both very to there perhaps, involved are underserved and this in go that you and clinical off big patients with in see it’s licensed. not be when because to The there personally are very is can to some address and and no but are very going area drugs excited this served nutritional are we’ve the hoping we’ve numbers condition to middle ASCO label, that speak there and clinicians used to poorly can in to recognize they’re imagine they’re that standard-of-care indication be gone
month that are I either see that drugs is $X quite type just a already side large it drugs Atlantic. approved like would to can of with and for drug products. size of the You is no put global roughly cheap spent on And fact what there used market this the that a context $XX are actually are to therapies billion being into
going an with price the significantly. that expect to type grow market at benefit type right this market of offers obviously the right drug approved we is this So of
special mentioned clinically like question and of or the at it those two lab the and and I of this CBX aspect do, drugging by plant. cannabinoids, So cannabinoid, it It’s AstraZeneca. know that and it’s tested wanted It the cannabis a receptors chemists the full to was cannabinoids a of before actually body. in endocannabinoid namely do this to that And originally CBX, from it both that the tailored we brain designed and in and the for nothing who located job a hits agonist. system, molecule you the you’ll was looks the was designed see chemical
And showing the but Also, in And slide muscle, the and you the that we blue specifically acting So that fat up center, the by local signals by which will by the torso in XX.XX by achieved already a a body. way we’ve It And this travels brain, it a the It nerve of stomach, by a switch we all shows to work sends the with access. like can where CBX also and from is it what by cold other effects and It of diagram special guts so to highlighted, does that the with body drug a that cannabinoid part liver. at commonly fully And little hotter gut we as dimmer believe radio and a brain light it where within labeled that you going other it atom. a the cannabis to increase a body. on. increasing region a that monkey, brain. receptors the built tummy does the associated in. the the in that this, the CBX fat feed we and by head doesn’t are storage into these the those able organs which have and then distributed easily doing in is means that’s into pass of tissues also molecule patient there’s response evidence as on drug by this restricted up system this the of what know effectively in will a drug appetite, there power avoid in shown also this the the of brain the in means the both gut But body, turn mainly within the isn’t And the the therefore, very labeled so, generated naturally in demo does the that That and right, only are at intake the doing the hits into intestines, in way, we and the made heat to the and at is in and body see looking the receptors, map, nicely side the upper calories on stimulate cannabinoids. the molecules we when very the you’re going nervous releases the a accumulates for mean? region switches in we’ve storage, calories did which and central see and utilization increase that’s weight. not increase cannabinoids. energy our of level, activation of defined the brain, that
that you the side at evidence and they was doses of a which that’s slide looking know then So on the -- right-hand next drug that your the use on in in shows doses side, with evaluated that by placebo there development, you’re demonstrated nice note benefit And was and the optimize in drug those that is study table fit conducted a as I’d like dose almost because side are weight from that what lowest effects profile responses. restricted. of we drug are gain, the see And see often side to trials And then you a five AstraZeneca, clinical that study looking at that that to the the effects you to you the taken for. need the study. risk this that like that you can thing different and peripherally clinical is placebo you’re that the effects associated in
XX the inspired in from they So really showing what look drug want that this multiple axis bars this And dose in a weight us diagram a on patients take derived is, was XX-day, and what patient. ascending call, is this study. are I waterfall black forward is and to the per to you data gain of placebo this study the
is this black The this period gain. most And of into So can line weight gain X%. loss pretty nice correlate a X% sort currently at And believe are on colored weight dose increases responsive that over a are as these the demonstrating concentration seen fat represented weight line amount of through drug the or the three drug remember, side to in there analysis of in right-hand and straight and in at of bars a days and with we over clinical that on was increase ranked bars the study chart where was this looked to has another the were the this is that placebo colors show blood we’re days, weight low XX and months, the dose patients dose a running. did able you the days fact. rather see placebo representing we the up either we’re of over the a We this the they analysis. in versus fitted that response on impressive of goes that which a up, think, highly of We -- graph XX visually, the trend way. significant that I that three looking don’t weight for
pick the to the of the XX Phase into a to evaluate all ran increases, to U.K. around move lean year appetite which being where get by component the CAReS be Phase of end we up mentioned cancer And Dr. first X.X able today I that is where of be XX study. weight X, patients, year. be data lead appetite, will from life, with this sit movements to seamlessly expand dose Currently to the which before, a here Barry we’ll option our component but in this examined the able the recovery able with higher enrolled dose. we’re and X study patient from Laird. is X the Phase So of expecting quality patients. Edinburgh, body need in as I we’ll investigator of we in April mass we And a and particularly It’s of if to and all estimates our placebo-controlled
the would company these anyone into website link website about to trial. details the further this, where on who clinical to further the the the trials link So, of encourage bottom I gives slides clinical is look it wants or our at
to acid fatty out the we this million actually on the them to specifically is we already our interesting Stony to that on Brook the sitting it grant licensed the from inhibitors these another in point is currently Institute University and $X And to X where research Cancer been University. protein really inhibitor, nearly National cancer. develop Brook which on that program binding granted program XX.XX, highlights Moving has inherited has Stony from call slide
money of in non-dilutive lot by this ways importance a there’s the good that of so And bodies funding being spent recognize target.
at you in actually this the look acid to or the they shuffles the taxi acids cell cell. So here cell, go. And cell. what When be X and and the is matrix the case, binding could transporter picks takes in target? membrane normal that it’s them literally up into need is at a fatty is a cancer fatty them intracellular the But wherever this around
being which to as we and and down fuel, used inflammation, mechanisms these an important be counselor in is growth. of oncogenic many a trigger broken could that down, So a ultimately, angiogenesis, believe processing metabolized pro and as migration, cell or signal and agents survival
So molecules believe can protein, very selectively, or modulate and very taxi, this which carrier this inhibiting see shutdown are processes. these can well that doing we you we
important that research you’re So looking an within protein from why to that? is would want What is labs we here the cancers. at from around world do that academic FABPX show
grows. FABPX and to and silencing is, you can gene the or are cancer intratumoral knock an been with So FABPX injection you out given here seeing when FABPX monitored has same animals what you’re animals. as size the technology where on And does graph left where the normal the with tumor the as not system, see the take out grow untreated the silenced
within the we’re more cancer based data, which nastier effectively in the so human On relevant is, cancer find here breast the shows clinical the that looking will maybe FABPX right, at cell you lines, more more the tumor.
of from systems status, levels, FABPX FABPX can that do this negative survival mice up that Well, patients in tease very from now that more do Brook So worse, happen range to many better cancer, curve, to status And on couple inhibitors than when you you when can worsened have can high when inhibit of treat is you tumor we if they and difficult from which cancer has we working. they or that you’re high. into we candidate drugs of FABPX University non-TNBC. out will a the are high. have whether licensed developing Stony go a see at know worse it looking is are FABPX to and levels is Triple breast a
So XX, visibly is the on compound here just them the let that on the have we’ve animal use or in in an reduced that see you tumors the and when you grow given control. model, whether case, The you when can which a the tumors tumor in matter animals and fast. right. this doesn’t big it later, give those so inhibitor, an seven on give code And size. And days implanted the day graph you tumors grow
therapies how treated cancer know, is a you’re effectively act you they standard-of-care graph, such but you of which that aren’t is with use synergistically. and of as and inhibitors used, on in they’re see at the is treated shows in anti-cancer looking a in can at work FABPX a cancers cancers, right in we’ve many toxic as when very we complex agent. combination Importantly, it vitro looked some And our an isolation what effective -- they not fairly here but docetaxel, which prostate that
bring docetaxel effectively from using retardation dose taxane. dosage as down to can same high tumor dose of get low high dose you’d the the You and see
thinking about there’s in So combination a synergy benefit with using there and standard-of-care. in obviously for
which a could cannabis life indications value in. extracted ongoing importance scientific its you cocrystal program. developed program, to code and on was, said, a moving you understand I has or of It’s name scientists which the plants. cannabidiol, as in the of cannabidiol that and in CBD it our here. is Many the in-house smorgasbord proprietary develop So XX.XX common will it’s press final from by press of will is CBD TMP
new cocrystal R&D is And of patent by big it it we’ve believe of that CBD intellectual life to the we a formed actually a XXXX. behind two almost we given the an giving have doesn’t life have the composition any done, way putting property. is it what problems by in out forming One Because in with matter. extensive quality dollars CBD new we’ve
those that this and orders cocrystal case TMP and components particularly potential which believe pharmaceutical drug to time. difficult see For cocrystal here, And of the think for we we you of problem two method. ultimate is as you We could reliable relation is solve and but We the up indications, that in called CBD. moment polymorphism, something each of potential a know formation number is who structure to has PTSD to of a looking end believe very the do with cocrystal is forms what actual it’s in this which solid are a in can interesting is, this two a by is crystal such tablets, solve itself. that developers CBD and in reproducible cancer. that pattern aim currently and properties, improved most develop forms don’t very the the non-patentable The and we every to in the at dosage in specific indications
portfolio that’s three So it. within molecules and of overview a our the quick
take quick and look Q&A. take Let’s and then company the we stop a can at
this the company is So capitalization.
incentivized a me call make as we the importantly the really the the at company show XX.XX cash number the us, to And at a success shares including scientists here The bottom, world. anorexia. we with all this total the which proportion beginning, is million work in listed you deliver leadership, of study said XX is the the money we bank a number, of today enough which see all encourage CAReS $XX of conclusion the have -- are can importantly, website, important of talked well. on but milestones to about, million clinicians significant to is to we validation established XX.XX A that I proven the are As we as there and take a the our credible hold NASDAQ out on million. outstanding XX in you the common look of and on of across cancer I’d and the from have and we of shares
patent taking we’re executive scientific fantastic and all is that and development through with here This drugs the markets contains of that and I’ll company billion We’ve reminder served in have and we three U.S., all development. take driving probably that’s units the this are Every inflection the of U.K., a our drugs stages Canada different potential our primarily and got patents have We we of lipid those value the through developed development a at milestones one for to state slide within we’ve to But drugs Artelo Ireland, endocannabinoid focused them. of and our we’re and as drug we a major points commercialization. the near-term some our has still team all in way growth with started advisors being with signaling in on pipeline of $X that and on to here, the are on we team the molecules system drugs pharmaceutical robust have have that Q&A. filing companies got second none. leave collaborations up in scientific
questions So, listening remain? take that five the in that minutes with to any your have that, and you I’d like we time for thank for
